Zhang L, He J, Yang F, Dang H, Li Y, Guo S, Li S, Cao C, Xu J, Li S, Zhou X
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); National Health Commission Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Shanghai 200025, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2023 Jun 13;35(3):217-224. doi: 10.16250/j.32.1374.2023073.
This report presented the endemic status of schistosomiasis and analyzed the data collected from the national schistosomiasis prevention and control system and national schistosomiasis surveillance program in the People's Republic of China in 2022. Among the 12 provinces (municipality and autonomous region) endemic for schistosomiasis, Shanghai Municipality, Zhejiang Province, Fujian Province, Guangdong Province and Guangxi Zhuang Autonomous Region continued to maintain the achievements of schistosomiasis elimination, and Sichuan and Jiangsu provinces maintained the criteria of transmission interruption, while Yunnan, Hubei, Anhui, Jiangxi and Hunan provinces maintained the criteria of transmission control by the end of 2022. A total of 452 counties (cites, districts) were found to be endemic for schistosomiasis in China in 2022, with 27 434 endemic villages covering 73 424 400 people at risk of infections. Among the 452 endemic counties (cities, districts), 75.89% (343/452), 23.45% (106/452) and 0.66% (3/452) achieved the criteria of elimination, transmission interruption and transmission control of schistosomiasis, respectively. In 2022, 4 317 356 individuals received serological tests for schistosomiasis, and 62 228 were sero-positive. A total of 208 646 individuals received stool examinations for schistosomiasis, with one positive and another two cases positive for urine microscopy, and these three 3 cases were imported schistosomiasis patients from Africa. There were 28 565 cases with advanced schistosomiasis documented in China by the end of 2022. snail survey was performed in 18 891 endemic villages in China in 2022 and snails were found in 6 917 villages (36.62% of all surveyed villages), with 8 villages identified with emerging snail habitats. Snail survey was performed at an area of 655 703.01 hm and 183 888.60 hm snail habitats were found, including 110.58 hm emerging snail habitats and 844.35 hm re-emerging snail habitats. There were 477 200 bovines raised in the schistosomiasis endemic areas of China in 2022, and 113 946 bovines received serological examinations for schistosomiasis, with 204 sero-positives detected. Among the 131 715 bovines received stool examinations, no positives were identified. In 2022, there were 19 726 schistosomiasis patients receiving praziquantel chemotherapy, and expanded chemotherapy was performed in 714 465 person-time for humans and 234 737 herd-time for bovines in China. In 2022, snail control with chemical treatment was performed at an area of 119 134.07 hm, and the actual area of chemical treatment was 65 825.27 hm, while environmental improvements were performed at an area of 1 163.96 hm. Data from the national schistosomiasis surveillance program of China showed that the mean prevalence of infections was both zero in humans and bovines in 2022, and no infection was detected in snails. These data demonstrated that the endemic status of schistosomiasis continued to decline in China in 2022, with 3 confirmed schistosomiasis patients that had a foreign nationality and all imported from Africa, and the areas of snail habitats remained high. Further improvements in the construction of the schistosomaisis surveillance and forecast system, and reinforcement of survey and control are required to prevent the re-emerging schistosomiasis.
本报告介绍了血吸虫病的流行状况,并对2022年从中华人民共和国国家血吸虫病预防控制体系和国家血吸虫病监测项目收集的数据进行了分析。在12个血吸虫病流行省份(直辖市和自治区)中,上海市、浙江省、福建省、广东省和广西壮族自治区继续保持血吸虫病消除成果,四川省和江苏省维持传播阻断标准,而云南省、湖北省、安徽省、江西省和湖南省截至2022年底维持传播控制标准。2022年,中国共有452个县(市、区)发现有血吸虫病流行,有27434个流行村,涉及73424400名感染风险人群。在452个血吸虫病流行县(市、区)中,分别有75.89%(343/452)、23.45%(106/452)和0.66%(3/452)达到血吸虫病消除、传播阻断和传播控制标准。2022年,4317356人接受了血吸虫病血清学检测,62228人血清学阳性。共有208646人接受了血吸虫病粪便检查,1人粪便阳性,另有2例尿液镜检阳性,这3例均为来自非洲的输入性血吸虫病患者。截至2022年底,中国有晚期血吸虫病病例28565例。2022年在中国18891个血吸虫病流行村开展了查螺,在6917个村(占所有调查村的36.62%)发现有螺,其中8个村发现有新出现的螺点。查螺面积为655703.01公顷,发现有螺面积183888.60公顷,其中新出现有螺面积110.58公顷,复现螺点面积844.35公顷。2022年中国血吸虫病流行区饲养牛477200头,113946头牛接受了血吸虫病血清学检测,检测到204头血清学阳性。在131715头牛接受粪便检查中,未发现阳性。2022年,有19726例血吸虫病患者接受吡喹酮化疗,全国开展扩大化疗714465人份、家畜化疗234737头份。2022年,化学灭螺面积119134.07公顷,实际药物灭螺面积65825.27公顷,环境改造面积1163.96公顷。中国国家血吸虫病监测项目数据显示,2022年人群和家畜感染率均为零,查螺未发现感染性钉螺。这些数据表明,2022年中国血吸虫病流行状况持续下降,有3例确诊血吸虫病患者为外籍,均从非洲输入,钉螺面积仍然居高不下。需要进一步完善血吸虫病监测预警体系建设,加强查螺灭螺工作,防止血吸虫病疫情反弹。